Pinometostat (EPZ‐5676) is a DOT1L inhibitor in phase I clinical trials for adult and paediatric MLL‐rearranged acute leukaemia,106, 107 however, it has not been tested in preclinical models of NB. Here, KMT2A is linked to neuroblastoma.